-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Around $10M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Around $10M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
Lifecore Biomedical
- The Trade: Lifecore Biomedical, Inc. (NASDAQ:LFCR) 10% owner Joshua Landes acquired a total of 627,746 shares an average price of $7.97. To acquire these shares, it cost around $5 million.
- What's Happening: Lifecore Biomedical recently received notice from Nasdaq regarding delayed quarterly report.
- What Lifecore Biomedical Does: Lifecore Biomedical, incorporated in 1986, operates as an integrated contract development and manufacturing organization in the United States and internationally..
Zymeworks
- The Trade: Zymeworks Inc. (NASDAQ:ZYME) 10% owner Ecor Capital LLC acquired a total of 985,100 shares at an average price of $9.84. To acquire these shares, it cost around $9.7 million.
- What's Happening: Zymeworks recently issued corporate update on key strategic priorities and outlook for 2023.
- What Zymeworks Does: Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics.
Don't forget to check out our premarket coverage here
Neogen
- The Trade: Neogen Corporation (NASDAQ:NEOG) Chief Operating Officer Edward Douglas Jones bought a total of 2,500 shares at an average price of $17.91. To acquire these shares, it cost around $44.77 thousand.
- What's Happening: Neogen recently reported better-than-expected Q2 results.
- What Neogen Does: Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety.
Check This Out: Investor Optimism Declines As Nasdaq Snaps 7-Day Win Streak
Although US stocks closed lower on Wednesday, there were a few notable insider trades.
尽管周三美国股市收低,但仍有一些值得注意的内幕交易。
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
当内部人士购买股票时,这表明他们对公司前景充满信心,或者他们认为股票很划算。无论哪种方式,这都预示着做多该股的机会。不应将内幕购买视为做出投资或交易决策的唯一指标。充其量,它可以为购买决定提供信心。
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
以下是最近一些值得注意的内幕收购。欲了解更多,请查看 本辛加的内幕交易 平台。
Lifecore Biomedical
生命科生物医学
- The Trade: Lifecore Biomedical, Inc. (NASDAQ:LFCR) 10% owner Joshua Landes acquired a total of 627,746 shares an average price of $7.97. To acquire these shares, it cost around $5 million.
- What's Happening: Lifecore Biomedical recently received notice from Nasdaq regarding delayed quarterly report.
- What Lifecore Biomedical Does: Lifecore Biomedical, incorporated in 1986, operates as an integrated contract development and manufacturing organization in the United States and internationally..
- 交易: Lifecore 生物医学有限公司 (纳斯达克股票代码:LFCR)10% 的所有者约书亚·兰德斯 共收购了 627,746 股股票 平均价格为7.97美元。收购这些股票的费用约为500万美元。
- 发生了什么: Lifecore Biomedical最近收到了纳斯达克关于延迟季度报告的通知。
- Lifecore 生物医学是做什么的: Lifecore Biomedical 成立于 1986 年,是一家综合合同开发和制造组织,在美国和国际上运营。
Zymeworks
Zymework
- The Trade: Zymeworks Inc. (NASDAQ:ZYME) 10% owner Ecor Capital LLC acquired a total of 985,100 shares at an average price of $9.84. To acquire these shares, it cost around $9.7 million.
- What's Happening: Zymeworks recently issued corporate update on key strategic priorities and outlook for 2023.
- What Zymeworks Does: Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics.
- 交易: Zymeworks Inc. 纳斯达克股票代码:ZYME)10% 所有者 Ecor Capital LLC 共收购了985,100股股票 平均价格为9.84美元。收购这些股票的成本约为970万美元。
- 发生了什么: Zymeworks最近发布了关于2023年关键战略优先事项和展望的公司最新消息。
- Zymeworks 的作用: Zymeworks BC Inc是一家临床阶段的生物制药公司,致力于下一代多功能生物疗法的发现、开发和商业化。
Don't forget to check out our premarket coverage here
别忘了在这里查看我们的上市前报道
Neogen
Neoge
- The Trade: Neogen Corporation (NASDAQ:NEOG) Chief Operating Officer Edward Douglas Jones bought a total of 2,500 shares at an average price of $17.91. To acquire these shares, it cost around $44.77 thousand.
- What's Happening: Neogen recently reported better-than-expected Q2 results.
- What Neogen Does: Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety.
- 交易: Neogen 公司 (纳斯达克股票代码:NEOG)首席运营官爱德华道格拉斯·琼斯 共购买了 2,500 股股票 平均价格为17.91美元。收购这些股票的成本约为44.77万美元。
- 发生了什么: Neogen最近公布的第二季度业绩好于预期。
- Neogen 的作用: 总部位于密歇根州兰辛的Neogen Corporation开发、制造和销售各种食品和动物安全产品。
Check This Out: Investor Optimism Declines As Nasdaq Snaps 7-Day Win Streak
看看这个: 随着纳斯达克连续7天上涨,投资者的乐观情绪下降
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧